NCT00990236 - Thrombelastography Based Dosing of Enoxaparin | Biotech Hunter

Enrollment

185

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Thromboembolic Complications

Interventions

DRUG

Enoxaparin dose adjusted Lovenox based on TEG

Enoxaparin doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R \< 1.0 min - increase dose by 10 mg BID; delta-R \>/= 1.0 min and \</= 2.0 min - no change; delta-R \> 2.0 min - decrease dose by 10 mg BID.

DRUG

Enoxaparin 30 mg BID

Enoxaparin dose of 30 mg twice a day without any adjustments

Trial Locations (3)

97239

Oregon Health & Science University, Portland

Unknown

University of Texas Health Science Center at Houston, Houston

University of Washington, Seattle